The Medicines Company (the “Company”) on November 25, 2019, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”), dated as of November 23, 2019, with Novartis AG (“Parent”), and Medusa Merger Corporation (“Purchaser”) and an indirect wholly-owned subsidiary of Parent. On January 6, 2020, pursuant to the terms of the Merger Agreement and in accordance with Section 251(h) of the DGCL, Purchaser was merged with and into the Company (the “Merger”), without a vote of the Company’s stockholders, with the Company continuing as the surviving corporation in the Merger and as an indirect, wholly-owned subsidiary of Parent. In accordance with the terms of the Merger Agreement, and effective as of the Effective Time, each of Alexander J. Denner, Geno J. Germano, John C. Kelly, Clive Meanwell, Paris Panayiotopoulos, Sarah J. Schlesinger and Mark Timney ceased to be a member from the Company’s board of directors of and a member of the committees of the Company’s board of directors. From and after the Effective Time, until the earlier of their resignation or removal or until successors are duly elected and qualified in accordance with applicable law, (i) Victor Bulto and Christian Klee, the directors of Purchaser at the Effective Time, shall be the directors of the surviving corporation and (ii) the officers of the Company at the Effective Time shall be the officers of the surviving corporation.